Resitu: minimally invasive surgical technology

Claes Post

Other Current assignments: General Partner STOAF III SCITECH, member of the Board of Vakona AB, Developeration AB, and STOAF III Venture Partners AB. Previous Adjunct Professor Uppsala University, Lund University and Karolinska Institute. Previous assignments include Vice President and Senior Vice President positions at Astra and Pharmacia, CEO and Board positions at many Life Science start-up companies, including Dicot AB, AroCell AB, and IDL Biotech AB. Also partner at Danske Life Science, venture partner HealthCap and Nordic Biotech, and Investment Manager at ALMI Invest. 

Published 2022-06-07


Resitu Medical AB
Rapsgatan 7B
Uppsala, Sweden

Resitu Medical AB is a Swedish Medical Device company founded in 2019. The company is developing instruments enabling safe removal of intact tissues by a revolutionary technology. The solution has the potential to create a paradigm shift in the management of breast cancer. The portfolio of instruments will speed up the process of cancer management using a minimally invasive approach and facilitating the way radiologists and surgeons work.

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.